Reply to Fusco et al. Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on “Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509”
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Elo, J.A.; Sun, H.H.B.; Park, C.M. Osteolytic lesion of the mandible in a 42-year-old female. Int. J. Clin. Correl. 2017, 1, 54–60. [Google Scholar]
- Extract from the Clinical Evaluation Report for Ibrance. 2018; Accessed from the Australian Public Assessment Reports for Prescription Medicines (AusPARs). Available online: //www.tga.gov.au/node/842736 (accessed on 23 February 2021).
- Goetz, M.P.; Toi, M.; Campone, M.; Sohn, J.; Paluch-Shimon, S.; Huober, J.; Park, I.H.; Trédan, O.; Chen, S.-C.; Manso, L.; et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J. Clin. Oncol. 2017, 35, 3638–3646. [Google Scholar] [CrossRef]
- Ogasawara, T.; Katagiri, M.; Yamamoto, A.; Hoshi, K.; Takato, T.; Nakamura, K.; Tanaka, S.; Okayama, H.; Kawaguchi, H. Osteoclast Differentiation by RANKL Requires NF-κB-Mediated Downregulation of Cyclin-Dependent Kinase 6 (Cdk6). J. Bone Miner. Res. 2004, 19, 1128–1136. [Google Scholar] [CrossRef] [PubMed]
- Sankar, U.; Patel, K.; Rosol, T.; Ostrowski, M.C. RANKL Coordinates Cell Cycle Withdrawal and Differentiation in Osteoclasts Through the Cyclin-Dependent Kinase Inhibitors p27KIP1and p21CIP1. J. Bone Miner. Res. 2004, 19, 1339–1348. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marcianò, A.; Guzzo, G.M.; Peditto, M.; Picone, A.; Oteri, G. Reply to Fusco et al. Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on “Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509”. Int. J. Environ. Res. Public Health 2021, 18, 10145. https://doi.org/10.3390/ijerph181910145
Marcianò A, Guzzo GM, Peditto M, Picone A, Oteri G. Reply to Fusco et al. Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on “Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509”. International Journal of Environmental Research and Public Health. 2021; 18(19):10145. https://doi.org/10.3390/ijerph181910145
Chicago/Turabian StyleMarcianò, Antonia, Gian Marco Guzzo, Matteo Peditto, Antonio Picone, and Giacomo Oteri. 2021. "Reply to Fusco et al. Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on “Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509”" International Journal of Environmental Research and Public Health 18, no. 19: 10145. https://doi.org/10.3390/ijerph181910145